Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi最新文献

{"title":"[Chinese expert consensus on the diagnosis and treatment of Burkitt lymphoma (2026)].","authors":"","doi":"10.3760/cma.j.cn121090-20260410-00186","DOIUrl":"10.3760/cma.j.cn121090-20260410-00186","url":null,"abstract":"<p><p>Burkitt lymphoma accounts for less than 5% of adult lymphomas and is clinically highly aggressive. Despite improved prognosis with dose-intensive therapy, Burkitt lymphoma remains a specific area of clinical and biological research, and there are currently no consensus recommendations regarding the diagnosis, treatment, and prognostic factors in adult patients. In order to strengthen the understanding of Burkitt lymphoma in our country, improve the diagnosis and treatment level, and help promote multi-center clinical research, the Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association and Lymphoma Expert Committee of Chinese Society of Clinical Oncology (CSCO) organized relevant experts to discuss and form this consensus on the basis of the relevant consensus on the diagnosis and treatment of Burkitt lymphoma, combined with the latest research progress both domestically and internationally.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 7","pages":"617-625"},"PeriodicalIF":0.0,"publicationDate":"2026-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575530/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Chinese expert consensus on the diagnosis and treatment of large granular lymphocytic leukemia (2026)].","authors":"","doi":"10.3760/cma.j.cn121090-20260313-00130","DOIUrl":"10.3760/cma.j.cn121090-20260313-00130","url":null,"abstract":"<p><p>Large granular lymphocytic leukemia (LGLL) is a disease primarily occurring in elderly populations, characterized by the clonal proliferation of cytotoxic lymphocytes. In recent years, significant progress has been made in both basic and clinical research on LGLL, particularly in the field of novel drug therapies. To improve the diagnostic, differential diagnostic, and standardized treatment levels of LGLL for medical professionals in China, Hematological Oncology Committee of China Anti-Cancer Association, Lymphoid Disease Group, Red Blood Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association, Chinese Workshop of Indolent Lymphomas have jointly formulated this version of the expert consensus.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"513-522"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907317","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The correlation between lymphocyte subsets before autologous hematopoietic stem cell transplantation and hematopoietic reconstruction and recurrence after transplantation in multiple myeloma].","authors":"L L Zhang, F R An, B B Xie, Y S Wang, J X Hou, H Qin, Y Dong, Z M Zhai, L L Tao","doi":"10.3760/cma.j.cn121090-20260115-00028","DOIUrl":"10.3760/cma.j.cn121090-20260115-00028","url":null,"abstract":"<p><p>The clinical data of 57 patients with multiple myeloma (MM) who underwent autologous hematopoietic stem cell transplantation (auto-HSCT) at the Second Affiliated Hospital of Anhui Medical University from July 2020 to August 2025 were retrospectively analyzed. Peripheral blood lymphocyte subsets before transplantation were detected by flow cytometry. Multivariate analysis showed that a higher infused CD34(+)cell count (<i>HR</i>=0.739, <i>P</i>=0.043) and a higher proportion of regulatory T cells before transplantation (<i>HR</i>=0.728, <i>P</i>=0.009) were independent favorable prognostic factors for rapid neutrophil engraftment. A higher infused CD34(+)cell count (<i>HR</i>=0.849, <i>P</i>=0.042) and a higher pre-transplant NK cell count (<i>HR</i>=0.991, <i>P</i>=0.038) were independent favorable prognostic factors for rapid megakaryocyte engraftment. With a median follow-up of 9.9 (0.5-55.0) months, a higher ratio of CD4(+) T-cell percentage to CD8(+) T-cell percentage before transplantation was an independent risk factor for progression-free survival (<i>HR</i>=1.627, 95% <i>CI</i>: 1.159-2.284, <i>P</i>=0.005). This study demonstrated that lymphocyte subsets before auto-HSCT are associated with the speed of hematopoietic reconstitution and the risk of relapse in MM patients.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"582-586"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575526/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Allogeneic hematopoietic stem cell transplantation for 510 patients with active relapsed/refractory acute myeloid leukemia: a real-world study].","authors":"X Y Man, M L Li, X H Fei, H Y Cheng, Y M Yin, R M Luo, S Q Zhang, J Y Gu, S Xue, W J Zhang, F Yang, Q H Man, Y X Yang, Z Q Tian, T T Li, L Yuan, H X Wen, W Wei, W J Wang, Y Wang, J B Wang","doi":"10.3760/cma.j.cn121090-20260120-00040","DOIUrl":"10.3760/cma.j.cn121090-20260120-00040","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the long-term survival outcomes of salvage allogeneic hematopoietic stem cell transplantation (R/R AML) . &lt;b&gt;Methods:&lt;/b&gt; This was a retrospective real-world study. We conducted a retrospective analysis of 510 patients with R/R AML who underwent allo-HSCT at Aerospace Center Hospital between July 2012 and December 2024. All patients had active disease before transplantation, defined as a bone marrow blast proportion of at least 5%. Overall survival (OS) and disease-free survival (DFS) were assessed using the Kaplan-Meier method, whereas the cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) were evaluated by competing-risk models. Univariate analysis was performed using the log-rank test, and multivariable analysis was conducted using Cox regression for survival outcomes and Fine-Gray regression for competing-risk outcomes to identify independent prognostic factors. &lt;b&gt;Results:&lt;/b&gt; In this cohort of 510 patients, the median follow-up duration was 50 months (range, 0-151 months). The estimated 10-year overall survival (OS) and disease-free survival (DFS) rates were 35.5% (95% &lt;i&gt;CI&lt;/i&gt;: 31.2% -40.5% ) and 33.2% (95% &lt;i&gt;CI&lt;/i&gt;: 29.1% -38.0% ), respectively. Multivariable analysis demonstrated that European LeukemiaNet (ELN) risk stratification was a core prognostic factor. Patients in the intermediate-risk (&lt;i&gt;HR&lt;/i&gt;=1.74, &lt;i&gt;P&lt;/i&gt;=0.002) and adverse-risk (&lt;i&gt;HR&lt;/i&gt;=1.97, &lt;i&gt;P&lt;/i&gt;&lt;0.001) categories had markedly lower OS and DFS rates. Mild-to-moderate chronic graft-versus-host disease (cGVHD) served as a protective factor for OS and DFS (both &lt;i&gt;P&lt;/i&gt;&lt;0.001). A diagnosis-to-transplant interval longer than 10 months (&lt;i&gt;HR&lt;/i&gt;=1.56, &lt;i&gt;P&lt;/i&gt;&lt;0.001) was correlated with poor survival outcomes. A higher infused CD34(+) cell dose (≥4.3×10(6)/kg) was independently associated with superior OS (&lt;i&gt;HR&lt;/i&gt;=0.64, &lt;i&gt;P&lt;/i&gt;&lt;0.001) and DFS (&lt;i&gt;HR&lt;/i&gt;=0.62, &lt;i&gt;P&lt;/i&gt;&lt;0.001). In competing-risk analysis, intermediate and adverse ELN risk stratification (&lt;i&gt;HR&lt;/i&gt;=2.73 and 2.90, respectively; both &lt;i&gt;P&lt;/i&gt;&lt;0.001) and elevated bone marrow blast percentage (≥50% ) (&lt;i&gt;HR&lt;/i&gt;=1.62, &lt;i&gt;P&lt;/i&gt;=0.037) were independently linked to increased relapse risk. Mild, moderate, and severe cGVHD, compared with no cGVHD (&lt;i&gt;HR&lt;/i&gt;=0.38, 0.13, and 0.24; &lt;i&gt;P&lt;/i&gt;&lt;0.001, &lt;i&gt;P&lt;/i&gt;&lt;0.001, and &lt;i&gt;P&lt;/i&gt;=0.015, respectively), and grade Ⅲ-Ⅳ acute graft-versus-host disease (aGVHD) (&lt;i&gt;HR&lt;/i&gt;=0.54, &lt;i&gt;P&lt;/i&gt;=0.033) were associated with a lower CIR. Regarding non-relapse mortality (NRM), grade Ⅲ-Ⅳ aGVHD (&lt;i&gt;HR&lt;/i&gt;=2.36, &lt;i&gt;P&lt;/i&gt;&lt;0.001) and severe cGVHD (&lt;i&gt;HR&lt;/i&gt;=2.74, &lt;i&gt;P&lt;/i&gt;&lt;0.001) were major risk factors, and advanced age (&lt;i&gt;HR&lt;/i&gt;=1.47, &lt;i&gt;P&lt;/i&gt;=0.033) was also associated with higher NRM. &lt;b&gt;Conclusions:&lt;/b&gt; This study indicates that long-term disease-free survival may be attained through salvage allo-HSCT in patients with R/R AML despite active disease at transplantation. Long-term outcomes are mainly determined by disease biology an","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"534-540"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[A retrospective analysis of clinicopathological features and efficacy in 51 patients with high-grade B-cell lymphoma with 11q abnormalities].","authors":"L Wang, G Gao, Y P Jin, D Y Wu, L Y Chang, X D Wei, K S Zhou, Q X Xia","doi":"10.3760/cma.j.cn121090-20260310-00127","DOIUrl":"10.3760/cma.j.cn121090-20260310-00127","url":null,"abstract":"<p><p>To investigate the clinicopathological features, molecular genetic characteristics, and efficacy of chemotherapy regimens with different intensities in high-grade B-cell lymphoma with aberrations in the long arm of chromosome 11 (HGBCL-11q), this study retrospectively analyzed the data of 51 patients with HGBCL-11q at Henan Cancer Hospital, summarized their clinical, pathological and molecular profiles, and compared the differences in therapeutic efficacy and survival outcomes between groups with different treatment intensities. The median age of the 51 patients was 52 (5 - 84) years, with a male-to-female ratio of 1.22:1, and the digestive system was the most common site of involvement (18/51, 35.3% ). The tumor cells exhibited a germinal center B-cell immunophenotype: 47 patients (92.2% ) showed variable c-Myc expression in tumor cells (the proportion of positive cells ranged from 20% to 85% ), 41 patients (80.4% ) were negative for Bcl-2 expression, and 47 patients (92.2% ) had a Ki-67 proliferation index ≥90%. Fluorescence in situ hybridization confirmed the absence of MYC gene rearrangement and the presence of characteristic aberrations in 11q; recurrently mutated genes included DDX3X (60.0%, 12/20), PCLO (50.0%, 10/20), TP53 (45.0%, 9/20) and GNA13 (40.0%, 8/20), et al. The complete response rate in the rituximab-containing high-intensity chemotherapy group was significantly higher than that in the non-high-intensity group [87.5% (21/24) <i>vs</i> 60.9% (14/23), <i>P</i>=0.036], with longer progression-free survival [ (62.7±3.9) months <i>vs</i> (41.7±6.5) months, <i>P</i>=0.014]. In conclusion, HGBCL-11q has distinctive clinicopathological manifestations and molecular genetic features, and rituximab-containing high-intensity chemotherapy can significantly improve the response rate and survival of patients.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"597-601"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Research advances in mesenchymal stem cell therapy for graft-versus-host disease].","authors":"W H Wang, X L Pei, J Y Luo, E L Jiang","doi":"10.3760/cma.j.cn121090-20250925-00444","DOIUrl":"10.3760/cma.j.cn121090-20250925-00444","url":null,"abstract":"<p><p>Graft-versus-host disease (GVHD) remains a severe complication after allogeneic hematopoietic stem cell transplantation, and effective treatment options remain limited, particularly for patients with steroid-refractory GVHD or failure of multiple lines of therapy. Mesenchymal stem cell (MSC) therapy has shown promise for the prevention and treatment of GVHD because of the low immunogenicity and immunomodulatory, anti-inflammatory, and tissue-reparative properties of MSC. To date, MSC-based products have been approved for the treatment of acute GVHD (aGVHD) in several countries, including China. Although MSC therapy is generally well tolerated, its broader clinical application remains challenged by substantial interindividual variability in therapeutic response, potential safety concerns, and the lack of harmonized standards for manufacturing and quality control. This review systematically summarizes recent clinical research on MSC-based interventions for GVHD and critically discusses their therapeutic prospects and current limitations, with the aim of informing standardized and precision-oriented clinical application of MSC therapy.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"604-610"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Chinese expert consensus on infection management in multiple myeloma patients treated with bispecific antibody (2026)].","authors":"","doi":"10.3760/cma.j.cn121090-20260211-00088","DOIUrl":"10.3760/cma.j.cn121090-20260211-00088","url":null,"abstract":"<p><p>Bispecific antibody (BsAb) is a novel immunotherapy for relapsed/refractory multiple myeloma (MM), which induces tumor cell killing by bridging T cells with tumor surface antigens and has significantly prolonged patient survival. However, the unique immune activation mechanism of BsAb leads to sustained T-cell activation, B-cell depletion, and hypogammaglobulinemia, markedly increasing infection risk in patients. The overall incidence of infection is 45.8% -80%, becoming a critical issue affecting treatment safety. With the widespread application of BsAb in China, understanding of related infections has been continuously deepened, and infection monitoring techniques, prevention protocols, and treatment strategies are also being optimized. To standardize the prevention and control of BsAb-related infections in MM patients in China, the Plasma Cell Disease Group, Chinese Society of Hematology, Chinese Medical Association and Chinese Myeloma Committee-Chinese Hematology Association have developed this consensus based on the latest evidence. This consensus mainly applies to the infection monitoring, prevention, and management during the treatment of BsAb in MM patients, aiming to enhance the recognition and management capability of infection-related complications and enable patients to achieve optimal progression-free survival and overall survival.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"523-533"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575518/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Treatment of POEMS syndrome with the DRd regimen in an elderly, frail, high-risk patient: a case report].","authors":"M Wang, Y Qiu, Z L Li","doi":"10.3760/cma.j.cn121090-20260225-00104","DOIUrl":"10.3760/cma.j.cn121090-20260225-00104","url":null,"abstract":"","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"602"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical characteristics and prognosis of acute myeloid leukemia patients with RUNX1 single-site and multiple-site gene mutations].","authors":"C Li, Y X Wu, X Ma, S N Chen, D P Wu, X H Hu","doi":"10.3760/cma.j.cn121090-20251020-00473","DOIUrl":"10.3760/cma.j.cn121090-20251020-00473","url":null,"abstract":"<p><p><b>Objective:</b> To compare the clinical characteristics and prognosis of patients with acute myeloid leukemia (AML) harboring single-site versus multi-site mutations in the RUNX1 gene. <b>Methods:</b> This study was a retrospective cohort study. 145 patients with RUNX1-mutated AML treated at the First Affiliated Hospital of Soochow University between June 2017 and June 2023 were selected. Single-site RUNX1 mutations were observed in 123 patients, whereas multi-site mutations were detected in 22 patients. The outcomes of interest included overall survival (OS), recurrence-free survival (RFS), and the first-course induction remission rate, defined as the sum of complete remission and complete remission with incomplete hematologic recovery. <b>Results:</b> A total of 145 patients with RUNX1-mutated AML were included, including 87 males and 58 females, with a median age of 49 years (range, 17-78 years). The two groups showed no significant differences in age, sex composition, peripheral blood counts at diagnosis, karyotype, fusion genes, or risk stratification (all <i>P</i>>0.05). The median number of co-occurring gene mutations was 3 (range, 0-11) in the single-site group and 5 (range, 2-10) in the multi-site group, indicating a significantly higher number in the latter (<i>P</i>=0.001). However, the distribution of co-occurring mutations did not differ significantly between groups (<i>P</i>>0.05). There were no significant between-group differences in the first-course induction remission rate (53.3% <i>vs</i> 50.0%, <i>P</i>=0.819), median OS (45.67 <i>vs</i> 36.53 months, <i>P</i>=0.942), or median RFS (17.13 <i>vs</i> 21.17 months, <i>P</i>=0.679). In the single-site mutation group, patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) achieved 3-year OS and RFS rates of 74.7% and 58.5%, respectively, significantly higher than the 31.2% and 27.9% among those without transplantation (both <i>P</i><0.001). In the multi-site mutation group, the 3-year OS and RFS rates were 69.2% and 69.2%, respectively, among allo-HSCT recipients, significantly higher than 33.3% and 0, respectively, among nonrecipients (<i>P</i>=0.003 and <i>P</i>=0.001, respectively). Multivariate Cox proportional hazards analysis identified allo-HSCT as an independent protective factor for OS (single-site group: <i>HR</i>=0.256, <i>P</i><0.001; multi-site group: <i>HR</i>=0.164, <i>P</i>=0.043) and RFS (single-site group: <i>HR</i>=0.528, <i>P</i>=0.025; multi-site group: <i>HR</i>=0.142, <i>P</i>=0.030) . <b>Conclusion:</b> Patients with AML harboring single-site and multi-site RUNX1 mutations did not differ significantly in clinical characteristics, treatment response, or long-term prognosis. Allo-HSCT was associated with improved survival outcomes in both groups.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"541-548"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Impact of the infused CD34(+) cell dose on hematopoietic reconstitution and transplant-related outcomes in newly diagnosed multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation].","authors":"B B Xie, F R An, L L Zhang, L L Tao, J X Hou, Z M Zhai, Y Dong, H Qin, Y S Wang","doi":"10.3760/cma.j.cn121090-20260118-00035","DOIUrl":"10.3760/cma.j.cn121090-20260118-00035","url":null,"abstract":"&lt;p&gt;&lt;p&gt;&lt;b&gt;Objective:&lt;/b&gt; To investigate the impact of different infused CD34(+) cell doses on hematopoietic reconstitution and transplant-related outcomes in patients with multiple myeloma (MM) undergoing autologous peripheral blood stem cell transplantation (auto-PBSCT) . &lt;b&gt;Methods:&lt;/b&gt; We retrospectively analyzed 57 newly diagnosed MM patients who underwent first auto-PBSCT at the Second Affiliated Hospital of Anhui Medical University between July 27, 2020 and August 29, 2025. Patients were stratified by infused CD34(+) cell dose into a low-dose group (&lt;4×10(6)/kg, &lt;i&gt;n&lt;/i&gt;=19) and a high-dose group (≥4×10(6)/kg, &lt;i&gt;n&lt;/i&gt;=38). The primary endpoints were time to neutrophil engraftment and time to platelet engraftment. Secondary endpoints included the duration of grade 3-4 neutropenia, duration of grade 3-4 thrombocytopenia, duration of febrile neutropenia, and platelet transfusion requirements. Secondary endpoints were adjusted for multiple comparisons using the Benjamini-Hochberg false discovery rate (FDR) procedure. Logistic regression was used to identify factors associated with neutrophil and platelet engraftment within 10 days. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), were analyzed using the Kaplan-Meier method and Cox regression analysis. &lt;b&gt;Results:&lt;/b&gt; The median infused CD34(+) cell dose was 5.30 (3.49, 9.35) ×10(6)/kg, and all patients achieved hematopoietic reconstitution. Compared with the low-dose group, the high-dose group had shorter time to neutrophil engraftment (median: 10.00 d &lt;i&gt;vs&lt;/i&gt; 11.00 d, &lt;i&gt;P&lt;/i&gt;=0.014) and platelet engraftment (median: 10.00 d &lt;i&gt;vs&lt;/i&gt; 12.00 d, &lt;i&gt;P&lt;/i&gt;=0.009). The high-dose group also had shorter duration of severe cytopenia, shorter febrile neutropenia duration, and lower platelet transfusion requirements (all &lt;i&gt;P&lt;/i&gt; value&lt;0.05). Multivariable analysis showed that an infused CD34(+) cell dose ≥4×10(6)/kg was independently associated with neutrophil engraftment within 10 days (&lt;i&gt;OR&lt;/i&gt;=4.661, 95% &lt;i&gt;CI&lt;/i&gt;: 1.322-16.435, &lt;i&gt;P&lt;/i&gt;=0.017), whereas ISS stage Ⅲ (&lt;i&gt;OR&lt;/i&gt;=0.217, 95% &lt;i&gt;CI&lt;/i&gt;: 0.060-0.781, &lt;i&gt;P&lt;/i&gt;=0.019) and a higher number of pre-transplant chemotherapy cycles (&lt;i&gt;OR&lt;/i&gt;=0.706, 95% &lt;i&gt;CI&lt;/i&gt;: 0.520-0.958, &lt;i&gt;P&lt;/i&gt;=0.025) were associated with failure to achieve platelet engraftment within 10 days. Survival analysis showed that the high-dose group had superior PFS and OS compared with the low-dose group (median PFS time: not reached vs 773 d, &lt;i&gt;P&lt;/i&gt;=0.040; median OS time: not reached &lt;i&gt;vs&lt;/i&gt; 812 d, &lt;i&gt;P&lt;/i&gt;=0.009), and that an infused CD34(+) cell dose ≥4×10(6)/kg might be independently associated with a lower risk of relapse or disease progression (&lt;i&gt;HR&lt;/i&gt;=0.212, 95% &lt;i&gt;CI&lt;/i&gt;: 0.052-0.870, &lt;i&gt;P&lt;/i&gt;=0.031) . &lt;b&gt;Conclusion:&lt;/b&gt; In patients with newly diagnosed MM undergoing auto-PBSCT, an infused CD34(+) cell dose ≥4×10(6)/kg was associated with faster neutrophil engraftment, shorter duration of severe myelosuppression, reduced tim","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"47 6","pages":"564-570"},"PeriodicalIF":0.0,"publicationDate":"2026-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13575513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148907338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}